Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin

Biomaterials

Volumn 32, Issue 9, 2011, Pages 2314-2326

  Kim, Pyung Hwan ^a   Sohn, Joo Hyuk ^b   Choi, Joung Woo ^a   Jung, Yukyung ^a   Kim, Sung Wan ^c,d   Haam, Seungjoo ^a   Yun, Chae Ok ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF UTAH   (United States)

^d Hanyang University   (South Korea)

Author keywords

Active targeting; Ad conjugated bioreducible polymer; Adenovirus; Cancer gene therapy; Hybrid vector

Indexed keywords

ACTIVE TARGETING; ADENOVIRUS; BIOREDUCIBLE POLYMER; CANCER GENE THERAPY; HYBRID VECTOR;

GENETIC ENGINEERING; TUMORS; VIRUSES;

GENE THERAPY;

ADENOVIRUS VECTOR; DWP 418; DWP 418 MACROGOL TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; MACROGOL; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; INJECTIONS, INTRAVENOUS; LIVER; MICE; ONCOLYTIC VIRUSES; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 78751706319     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.031     Document Type: Article

References (39)

1. Kreppel F., Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008, 16:16-29.
2. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5:965-976.
3. Yun C.O. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 2008, 10:356-361.
4. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005, 16:1016-1027.
5. Peng Z., Yu Q., Bao L. The application of gene therapy in China. IDrugs 2008, 11:346-350.
6. Raty J.K., Pikkarainen J.T., Wirth T., Yla-Herttuala S. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol 2008, 1:13-23.
7. Mok H., Palmer D.J., Ng P., Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005, 11:66-79.
8. Alemany R., Suzuki K., Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, 81:2605-2609.
9. Doronin K., Shashkova E.V., May S.M., Hofherr S.E., Barry M.A. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009, 20:975-988.
10. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999, 10:1349-1358.
11. Maeda M., Kida S., Hojo K., Eto Y., Gaob J.Q., Kurachi S., et al. Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg Med Chem Lett 2005, 15:621-624.
12. Eto Y., Gao J.Q., Sekiguchi F., Kurachi S., Katayama K., Maeda M., et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005, 7:604-612.
13. Kreppel F., Gackowski J., Schmidt E., Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005, 12:107-117.
14. Oh I.K., Mok H., Park T.G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug Chem 2006, 17:721-727.
15. Ogawara K., Kuldo J.M., Oosterhuis K., Kroesen B.J., Rots M.G., Trautwein C., et al. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res Ther 2006, 8:R32.
16. Eto Y., Yoshioka Y., Asavatanabodee R., Mizuguchi H., Mukai Y., Okada N., et al. Development of pegylated adenovirus vector for cancer gene therapy. Yakugaku Zasshi 2008, 128:1733-1742.
17. Lanciotti J., Song A., Doukas J., Sosnowski B., Pierce G., Gregory R., et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003, 8:99-107.
18. Ogawara K., Rots M.G., Kok R.J., Moorlag H.E., Van Loenen A.M., Meijer D.K., et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004, 15:433-443.
19. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
20. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
21. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
22. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
23. Jung Y., Park H.J., Kim P.H., Lee J., Hyung W., Yang J., et al. Retargeting of adenoviral gene delivery via herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 2007, 123:164-171.
24. Kim E., Kim J.H., Shin H.Y., Lee H., Yang J.M., Kim J., et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003, 14:1415-1428.
25. Kim J., Cho J.Y., Kim J.H., Jung K.C., Yun C.O. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002, 9:725-736.
26. Kim J.H., Lee Y.S., Kim H., Huang J.H., Yoon A.R., Yun C.O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006, 98:1482-1493.
27. Green N.K., Herbert C.W., Hale S.J., Hale A.B., Mautner V., Harkins R., et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004, 11:1256-1263.
28. Alemany R., Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001, 8:1347-1353.
29. Leissner P., Legrand V., Schlesinger Y., Hadji D.A., van Raaij M., Cusack S., et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 2001, 8:49-57.
30. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001, 75:11284-11291.
31. Yun C.O., Yoon A.R., Yoo J.Y., Kim H., Kim M., Ha T., et al. Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity. Hum Gene Ther 2005, 16:248-261.
32. Gao J.Q., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 2007, 122:102-110.
33. Eto Y., Yoshioka Y., Mukai Y., Okada N., Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008, 354:3-8.
34. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006, 6:215-226.
35. Elkon K.B., Liu C.C., Gall J.G., Trevejo J., Marino M.W., Abrahamsen K.A., et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci U S A 1997, 94:9814-9819.
36. Zaiss A.K., Liu Q., Bowen G.P., Wong N.C., Bartlett J.S., Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002, 76:4580-4590.
37. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol 1995, 13:86-91.
38. Tsutsumi Y., Tsunoda S., Kaneda Y., Kamada H., Kihira T., Nakagawa S., et al. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors. Jpn J Cancer Res 1996, 87:1078-1085.
39. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004, 10:8293-8300.